Avivagen Inc.

TSXV Exchange | Aug 13, 2020, 8:02 AM EDT | Real-time price

VIV $ 0.43 RT
0.01 (2.381%)
Day Low: 0.00
Day High: 0.00
Avivagen Inc. Announces Stock Option Grants

OTTAWA, Ontario

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that its Board of Directors has approved the issuance of 545,000 stock options, including options granted to officers and directors of the Corporation. The options, which shall be vested over an eight-quarter period, are exercisable up to five years from the issuing date, and have a strike price of $0.61 These options form part of a total remuneration package for directors, officers and employees of Avivagen.

Option grants are subject to approval of the TSX Venture Exchange.

For further information on Avivagen's public disclosure file, consult SEDAR at

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim,” “anticipate,” “appear,” “believe,” “consider,” “could,” “estimate,” “expect,” “if,” “intend,” “goal,” “hope,” “likely,” “may,” “plan,” “possibly,” “potentially,” “pursue,” “seem,” “should,” “whether,” “will,” “would” and similar expressions. Statements about OxC-beta’s ability to replace antibiotics commonly added to livestock feeds or to fulfill the global mandate to remove in-feed antibiotics as growth promoters, are forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not the gain market acceptance or regulatory approvals necessary to fulfill the global mandate to remove in-feed antibiotics as growth promoters. Readers are referred to Avivagen’s latest annual information form and management’s discussion and analysis available at for a discussion of risks associated with its business. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

Avivagen Inc.
Drew Basek
Director of Investor Relations
Phone: 416-540-0733

Kym Anthony
Chief Executive Officer
Office Phone: 613-949-8164

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.